Results from a Swedish study shows that two thirds of the dogs that took part
in the research recovered. The unique results were presented in Cambridge on
Sunday.
The study was performed by the pharmaceutical company Oasmia Pharmaceutical in
co-operation with the Swedish University of Agricultural Studies in Uppsala. It
is the first successful study using the cancer drug substance paclitaxel in
dogs. Earlier attempts published have failed because of severe side-effects.
The new pharmaceutical Paclical® Vet containing paclitaxel is given as an
infusion for 15 minutes every third week until the tumour decreased
significantly in size or vanished completely.
- It really is astonishing results that has exceeded all my expectations, says
veterinarian Patricio Rivera who has worked with the dogs at the Department of
Clinical Sciences at SLU.
The results from the study was presented at the annual veterinary oncological
conference in Cambridge, England, shows that earlier incurable tumour diseases
in dogs can now be treated. The interest among the participating veterinarians
was great.
The company Oasmia and CEO Julian Aleksov counts on a big impact among
veterinarians world-wide. The results improve the company's product portfolio,
especially the pharmaceutical Paclical® for human use.
- We expect that Paclical® Vet will be registered during 2008 as the first
veterinary cancer drug in the world, Aleksov says.
There are over 140 million dogs in the EU and USA. Approximately 50% of all
dogs older than 6 years develop cancer in some form.
Oasmia Pharmaceutical is a pharmaceutical company that specialises in the
treatment of severe diseases. Oasmia develops pharmaceuticals for the future.
A pharmaceutical company based on the latest concepts in bio-organic chemistry.
The main idea is to improve the treatment of serious diseases. Primarily, this
development is in oncology and treatment with cytostatics but Oasmia also
conducts research in antibiotics, asthma and neurological diseases. Oasmia has
in-house production capacity of pharmaceuticals for clinical trials, both
company related and others. Oasmia has developed several products based on
existing pharmaceuticals in a new environment, which leads to whole new
solutions for cancer treatment. These products give Oasmia a solid product
portfolio within oncology with several products in clinical or pre-clinical
phase.
Oasmia is noted on NGM Nordic MTF.
More information is available at www.ngm.se or www.oasmia.com.
For further information contact info@oasmia.com or call +46 18 50 54 40.
